High hopes for Cellceutix’ Brilacidin for serious skin infections

14 October 2013

US clinical-stage biopharmaceutical company Cellceutix (OTCQB: CTIX) says that it is completing the required documentation to begin a Phase IIb clinical trial of Brilacidin (formerly PMX-30063) as a new drug candidate for acute bacterial skin and Skin structure infections (ABSSSI).

Brilacidin came under the control of Cellceutix last month with the firm’s acquisition of assets belonging to PolyMedix from the bankruptcy court (The Pharma Letter September 9).

Based upon what Cellceutix says it can only describe as “exceptional results” in a completed Phase IIa trial and building on guidance from prior meetings regarding Brilacidin with the Division of Anti-Infective Products of the US Food and Drug Administration, Cellceutix is planning to advance the clinical development of Brilacidin in a Phase IIb dose-optimization clinical trial. The trial will include a single-dose regimen as well as a three-day dosing regimen using Brilacidin for the treatment of ABSSSI caused by Staphylococcus aureus (including MRSA) and Streptococcus pyogenes. Cellceutix believes that, based on consultation, the trial will begin in January 2014.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical